LAUREN ELSENER: Open Payments
NPI 1457590002 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,335 in 194 payments from 23 companies in 2025. Trend: 2023 $3,236 · 2024 $3,255 · 2025 $3,335
Food & beverage: $3,205Education: $131
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $305 |
| Botanix SB Inc | 16 | $280 |
| ABBVIE INC. | 22 | $275 |
| Janssen Biotech, Inc. | 12 | $241 |
| UCB, Inc. | 10 | $220 |
| REVANCE THERAPEUTICS, INC. | 4 | $206 |
| Regeneron Healthcare Solutions, Inc. | 13 | $204 |
| Galderma Laboratories, L.P. | 17 | $194 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $187 |
| Arcutis Biotherapeutics, Inc. | 21 | $161 |
Products named: DUPIXENT, SOFDRA, TREMFYA, Bimzelx, DAXXIFY, SKYRIZI, NEMLUVIO, Zoryve.
Industry payments across TX — which companies pay providers there.
